» Articles » PMID: 32467422

Effects of the COVID-19 Pandemic on the Management of Patients With ST-elevation Myocardial Infarction in a Tertiary Cardiovascular Center

Abstract

Background: In the Coronavirus Disease 2019 (COVID-19) pandemic, the appropriate reperfusion strategy in patients with ST-segment elevation myocardial infarction (STEMI) is unclear.

Methods: This retrospective single-center study consecutively enrolled patients who presented with STEMI and scheduled for primary percutaneous coronary intervention (PPCI) during the outbreak of COVID-19. Due to the delay in the reporting of the polymerase chain reaction test results, our postprocedural triage regarding COVID-19, followed by the isolation strategy, was based on lung computerized tomography scan results.

Results: Forty-eight patients with STEMI referred to our center. PPCI was done for 44 (91%) of these patients. The mean symptom-to-device time was 490.93 ± 454.608 minutes, and the mean first medical contact-to-device time was and 154.12 ± 36.27 minutes. Nine (18%) patients with STEMI were diagnosed as having typical/indeterminate features indicating COVID-19 involvement. During hospitalization, 1 (2.0%) patient died of cardiogenic shock. The study population was followed for 35.9 ± 12.7 days. Two patients expired in another centers due to COVID-19. No cardiac catheterization laboratory staff members were infected by COVID-19 during the study period.

Conclusions: Our small report indicates that by taking the recommended safety measures and using appropriate PPE, we can continue PPCI as the main reperfusion strategy safely and effectively.

Citing Articles

The Pragmatic Role of COVID-19 on the Thrombus Grade of Patients with Contemporary ST-Segment-Elevation Myocardial Infarction.

Firouzi A, Hosseini Z, Norouzi Z, Hosseini Z, Amirpour A, Talakoob H J Tehran Heart Cent. 2023; 17(3):103-111.

PMID: 37252079 PMC: 10222945. DOI: 10.18502/jthc.v17i3.10842.


The Impact of the Early COVID-19 Pandemic on ST-Segment Elevation Myocardial Infarction Presentation and Outcomes-A Systematic Review and Meta-Analysis.

Furnica C, Chistol R, Chiran D, Stan C, Sargu G, Girlescu N Diagnostics (Basel). 2022; 12(3).

PMID: 35328141 PMC: 8947375. DOI: 10.3390/diagnostics12030588.


Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study.

Erol M, Kayikcioglu M, Kilickap M, Guler A, Yildirim A, Kahraman F Anatol J Cardiol. 2020; 24(5):334-342.

PMID: 33122486 PMC: 7724394. DOI: 10.14744/AnatolJCardiol.2020.98607.

References
1.
Wang Y, Wang Y, Chen Y, Qin Q . Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020; 92(6):568-576. PMC: 7228347. DOI: 10.1002/jmv.25748. View

2.
Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

3.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

4.
Bates E, Topol E . Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 1991; 18(4):1077-84. DOI: 10.1016/0735-1097(91)90770-a. View

5.
Castelletti S . A Shift on the Front Line. N Engl J Med. 2020; 382(23):e83. DOI: 10.1056/NEJMp2007028. View